Harari Lab Posters

From Human Oncology

Harari Lab Directions Members Publications Posters Protocols Links

2007 Posters

• Dual Agent Targeting of EGFR and ErbB2 with Cetuximab and 2C4: A Strategy to Overcome Acquired Resistance to Cetuximab (Multidisp. H&NCancer Symp, Palm Springs 2007) (.pdf)

• Alterations of EGFR Trafficking and Degradation in EGFR-inhibitor Resistant Tumor Cells (AACR 2007, Poster #2348) (.pdf)

• Acquired Resistance to Cetuximab; Rationale for Sequential Therapies Targeting the EGFR, Molecular Targets of Cancer; Keystone Symposia, Whistler, British Columbia, 2007.

2006 Posters:

• Development and characterization of EGFR inhibitor resistant lines, A model to study acquired resistance to EGFR blockade (AACR Mol. Diag. in Cancer Ther. Dev., Chicago 2006)

• Array-based Identification of Genes and Proteins Associated with Resistance to EGFR Inhibitors (AACR 2006, Poster #1246)

• Potential Mechanisms of Acquired Resistance to EGFR Inhibitors (AACR 2006, Poster #1244)

2005 Posters:

• Enhancement of Tumor Response with Combination of Bevacizumab and Cetuximab (IASLC 2005)

• Radiation response Profiles in EGFR Inhibitor-Resistant Human Tumor Cells (AACR 2005, Poster #5057)

• Inhibition of Insulin-like Growth Factor-1 Receptor Signaling Impairs Proliferation of Head and Neck, Lung, Prostate and Breast Cancer Cells (AACR 2005, Poster #5041)

• Enhancement of Radiation Response with Bevacizumab: Influence of Treatment Sequence (AACR 2005, Poster#546)

2004 Posters:

• Establishment of Acquired Resistance to Epidermal Growth Factor Receptor (EGFR) Inhibitors in Human Tumor Cell Lines. (AACR 2004, Poster #5333)

• Modification of Radiation and EGFR Inhibitor Response in Human Tumor Cells Following Establishment of Radiation Resistance (ASTRO 2004, #2018)

• Modulation of Radiation Response by Histone Deacetylase Inhibition in Human Cancer Cell Lines. (ASTRO 2004)

• Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. (ASCO 2004)

2003 Posters

• Dual Agent Molecular Targeting of the Epidermal Growth Factor Receptor: Combining Anti-HER1/EGFR Monoclonal Antibody with Tyrosine Kinase Inhibitor (AACR 2003, Poster #3777)

• Radiosensitization following EGFR signaling inhibition by Erlotinib. (ASTRO 2003)

2002 Posters

• Modulation of Radiation Response and Tumor-induced Angiogenesis Following EGFR Signaling Inhibition by ZD1839 ('Iressa')* in Human Squamous Cell Carcinomas (AACR 2002, Poster #259)